Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for managing type 2 diabetes due to its efficacy in enhancing insulin secretion and facilitating weight loss. Despite its benefits, concerns have arisen regarding the potential risk of acute pancreatitis (AP) associated with GLP-1 RA use. Although the Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial did not show a significant increase in AP risk with semaglutide, some studies indicate a possible link between GLP-1 RAs and pancreatic inflammation. This case is about a patient with AP who was recently started on semaglutide. The increasing use of GLP-1 RAs necessitates awareness of their potential to cause pancreatic complications, underscoring the need for ongoing research and clinical vigilance to better understand and manage this risk.
No takes yet. Share an insight, caveat, or question.
R - Princy (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: